Skip to content

Safety and efficacy of rapamycin-eluting stent in the treatment of unprotected left main coronary artery stenosis in older adult patients with degenerative coronary atherosclerotic heart disease

Safety and efficacy of rapamycin-eluting stent in the treatment of unprotected left main coronary artery stenosis in older adult patients with degenerative coronary atherosclerotic heart disease

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800016413
Enrollment
Unknown
Registered
2018-06-01
Start date
2018-08-01
Completion date
Unknown
Last updated
2018-06-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary atherosclerotic heart disease

Interventions

1:rapamycin-eluting stents
2:Coronary artery bypass grafting

Sponsors

Taihe Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Patients with degenerative coronary atherosclerotic cardiovascular disease as confirmed by imaging examination. Diagnostic criteria are myocardial damage caused by an imbalance between coronary blood flow and cardiac muscle requirements due to changes in the coronary circulation. This occurs because of functional and/or changes; (2) Coronary angiography shows that the lesion in the left main coronary artery is unprotected, and over 50% of the left main coronary artery is necrotic; (3) Coronary angiography shows that there are more than two target lesions in the main coronary arteries; (4) Aged 60-75 years; (5) Provision of written informed consent.

Exclusion criteria

Exclusion criteria: (1) Presence of left main coronary artery disease caused by factors rather than coronary atherosclerosis; (2) Diseases such as stroke, malignant tumor, traumatic brain injury that influence the follow-up results; (3) Surgical contraindications such as severe diabetes mellitus, liver disease and abnormal blood coagulation; (4) Participating in other clinical trials.

Design outcomes

Primary

MeasureTime frame
The rate of repeat revascularizations in the target lesion;

Secondary

MeasureTime frame
The rate of repeat revascularizations in the target lesion;Rate of restenosis;Mortality;Cause of death;Survival time;Angiographic appearance of diseased vessels;

Countries

China

Contacts

Public ContactWei Chen

Taihe Hospital

doctorchenwei88@163.com+86 18671918088

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 25, 2026